Articles tagged with Glioblastomas
Researchers found adding hydroxyurea to current chemotherapy protocol significantly increased survival in animal models of glioblastoma, a deadly brain cancer. The combination led to a significant increase in survival and even induced remission in some cases.
Researchers found that combining temozolomide with the enzyme inhibitor SLC-0111 significantly regressed human-derived glioblastoma, improving patient outcomes. The treatment strategy targets carbonic anhydrase 9, a membrane enzyme involved in tumor growth.
Glioblastoma, a type of brain cancer with a grim prognosis, may be treatable more effectively when administered at specific times of day. Researchers found that the circadian rhythm controls daily rhythms in a key protein associated with tumor growth, and inhibiting its activity can reduce invasive properties.
Scientists have discovered a novel mechanism that prevents glioblastoma development through the modulation of EFGR expression by RanBP6. The study reveals that silencing of RanBP6 promotes glioma growth by upregulating EGFR expression, while reconstitution of RanBP6 leads to reduction in tumor growth.
A Northwestern Medicine study reveals autophagy's promoting role in malignant glioblastoma and identifies MST4 and ATG4B as key players. Inhibiting ATG4B with radiotherapy significantly slows tumor growth, increasing overall survival rates.
Researchers have identified a genetically distinct subpopulation of patients with glioblastoma that is particularly sensitive to drugs like cilengitide. The strategy uses a gene profile alone to predict which tumors are susceptible to αvβ3 blockade, offering a new therapeutic target for precision medicine in brain cancer treatment. Thi...
Researchers have developed a new therapy that blocks the TRF1 protein, which is essential for protecting telomeres in glioblastoma cells. This approach has shown promising results in mouse models, with a significant increase in survival rates and reduction in tumour growth.
Ludwig Cancer Research researchers will present findings on cancer cell metabolism, tumor microenvironment, and potential therapeutic targets. They will also discuss the use of immunotherapy to treat brain cancer, including results from a Phase 2 clinical trial.
Preclinical studies demonstrate onalespib's effectiveness in inhibiting HSP90, reducing cell-survival proteins and tumor growth. The agent shows promise as a single treatment or in combination with temozolomide for glioblastoma patients.
Researchers have developed a comprehensive genomic sequencing approach that guides timely treatment for recurring brain cancer, resulting in extended progression-free survival. Two patients survived over a year without disease recurrence, demonstrating the potential of precision medicine in aggressive and refractory tumors.
Researchers found that arsenic trioxide can be a powerful therapy for glioblastoma multiforme, extending patient survival by three to four times. The treatment targets specific genomic signatures of brain tumor cells, allowing for precision medicine and matching the right drug to the right patient.
A research team led by Dr. Claudia Barros aims to understand the cellular changes leading to glioblastoma brain tumor development. Using a Drosophila fruit fly model, they visualize cancer stem cells and identify early molecular changes.
Scientists at Mount Sinai & Sema4 validated a biomarker indicative of glioblastoma patient prognosis and likely response to therapies. BUB1B-sensitive tumors had significantly worse prognosis but were more likely to respond to many drugs already in clinical use.
Patients diagnosed at high-volume centers are up to 40% more likely to receive treatment for glioblastoma and live approximately three and a half months longer than those treated at low-volume centers. The study suggests that patients benefit from care at hospitals treating a high number of brain tumor patients.
Researchers have found that Zika virus preferentially infects and kills glioblastoma stem cells compared to other cell types. A mutant strain of the virus shows promise in slowing tumor growth and extending lifespan when combined with chemotherapy, offering a new potential treatment for brain cancer.
Researchers discovered a novel molecular mechanism that maintains glioma stem cells, which are responsible for tumorigenesis, treatment resistance, and tumor recurrence in glioblastoma. A small molecule inhibitor CMP3a selectively inhibits NEK2 kinase activity to promote tumor growth and radiation resistance.
Researchers found genetically modified CAR T cells successfully migrated to and penetrated glioblastoma tumors, but triggered an immunosuppressive tumor microenvironment. To overcome resistance, existing immunotherapies targeting checkpoint inhibitors may be necessary.
Research identified PTPRZ as a crucial enzyme for glioblastoma's maintenance and tumorigenicity. Pharmacological inhibition of PTPRZ shows promise in treating malignant gliomas.
A study published in Cell Reports found that altering the levels of microRNA miR-128 can induce a more homogeneous subtype of glioblastoma cells, making them more responsive to treatment. This discovery opens the door for using miR-128 as a therapeutic agent.
A research team has revealed intrinsic gene expression patterns of glioblastoma tumors, which could drive more effective treatments. The study found that tumor microenvironment cells contribute to the 'ecosystem' of hundreds of GBM tumors, influencing treatment outcomes and response to immunotherapy.
Researchers found that PTEN, a frequently deleted tumor suppressor gene in cancer, can regulate oncogene expression by increasing the deposition of DAXX and H3.3 onto chromatin. The study showed that eliminating both genes led to a synthetic growth defect, slowing down tumor growth.
Recent studies by TGen and UNC Lineberger researchers provide insight into glioblastoma's evolution and how to combat this aggressive brain tumor. The studies reveal that mutations affect how cancer starts and evolves, while combining drugs targeting PI3K and MAPK pathways show promise as a therapeutic approach.
A vaccine combining with high-dose chemotherapy improved glioblastoma patients' progression-free and overall survival. The vaccine targeted CMV antigen pp65, which is expressed in 90% of GBM tumors.
A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination to be well tolerated while also resulting in unexpectedly significant survival increases. The researchers found that the combination significantly slowed the progression of...
Lauren Sciences LLC has received the second grant from Voices Against Brain Cancer to continue developing LAUR-401, its innovative V-Smart Nanomedicine for Glioblastoma Multiforme. The award confirms the successful development of LAUR-401 and anticipates its potential as a transformative therapeutic for brain cancer patients.
Researchers found a way to inhibit glioblastoma growth by targeting neurodevelopmental transcription factors, which drive brain tumor growth. A chemotherapy drug called mithramycin can prevent further tumor growth with minimal side effects.
A new classification system for glioblastoma, a lethal brain cancer, has been developed by incorporating molecular variables. The refined model significantly improves the prognosis of patients treated with radiation and temozolomide, offering better clinical decision-making options.
A study by TGen has identified aurintricarboxylic acid (ATA) as a compound that can improve drug development against glioblastoma. ATA blocks the chemical cascade that allows glioblastoma cells to invade normal brain tissue and resist chemotherapy and radiation therapy.
A study suggests targeting the RAD51 protein could increase the effectiveness of radiotherapy in killing off glioblastoma cells, a subgroup of brain tumour cells that are resistant to treatment. Glioblastoma is the most common and aggressive type of primary brain tumour in adults, with a poor prognosis.
A new research from Michigan Medicine supports combining immune checkpoint blockade with gene therapy to fight gliomas. The approach showed stronger results when used in combination with either depletion of immunosuppressive cells or immune checkpoint blockade.
Researchers from the National Foundation for Cancer Research (NFCR) have discovered a new pharmacological agent to treat glioblastoma multiforme, a deadly brain cancer. The treatment has shown profound survival benefits in pre-clinical models when combined with radiation.
Researchers found that localized chemotherapy delivered directly to the brain improved survival rates in mice with glioblastoma when combined with immunotherapy. The study suggests that systemic chemotherapy weakens the immune system and may hinder its ability to fight tumors.
Researchers at Stanford University School of Medicine found that a subgroup of glioblastoma patients with highly vascularized tumors benefited from anti-angiogenic therapies, living an average of one year longer than those without. The study highlights the importance of properly categorizing tumors to personalize treatment.
A new biomarker enzyme ALDH1A3 has been identified in mesenchymal glioma stem-like cells, which are responsible for the tumorigenicity of glioblastoma multiforme tumors. The researchers have developed a small molecule inhibitor GA11 that targets this enzyme and has shown potent efficacy in preclinical testing.
Scientists identified a gene NAMPT that fuels glioblastoma growth and resistance to radiation therapy. Inhibiting NAMPT may improve treatment outcomes for most aggressive forms of the disease.
Researchers at Dartmouth's Norris Cotton Cancer Center have identified the functional role of two distinct DNA modifications, 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5-hmC), in glioblastoma tissues. The study found that 5hmC signatures had a strong association with patient survival.
Researchers at MD Anderson Cancer Center identified a pathway by which cancer cells spread in the brain, opening up new possibilities for treatment. They found that the gene WNT5A enables glioma stem cells to transition into GdECs, leading to aggressive tumor growth and disease recurrence.
A study by Ludwig Cancer Research identified a metabolic vulnerability in glioblastoma cells that can be exploited for therapy. GBM cells are extremely dependent on imported cholesterol and shutting down their import controls leads to dramatic cancer cell death and tumor shrinkage.
Researchers found that depriving brain tumor cells of cholesterol specifically kills them and causes tumor regression. This alternative method targets glioblastomas, the most aggressive form of brain cancer, which are difficult to treat due to their biochemical composition and blood-brain barrier.
Researchers have created a new method to combat glioblastomas, a type of brain tumor that is difficult to treat. The method involves testing multiple substances on individual cancer cells from each patient and identifying effective combinations for treatment.
A study published in Neurosurgical Focus reports the use of a minimally invasive laser procedure to treat large, 'inoperable' brain tumors, including glioblastomas. The procedure combines laser interstitial thermotherapy with a small craniotomy to remove cooked tumors and prevent swelling.
Researchers discovered that glioblastoma cells inhibit caspase-3 activity in microglia, leading to a tumor-stimulating phenotype. This inhibition causes microglia to stimulate tumor cells instead of attacking them.
Systems biologist Jan Philipp Junker and molecular geneticist Gaetano Gargiulo have each received a €1.5 million ERC Starting Grant to study cellular processes in zebrafish and glioblastoma, respectively. Their research aims to understand the mechanisms behind variable phenomena in developmental biology.
Researchers found that immune checkpoint blockade improved survival and promoted immune cell infiltration into tumors when combined with an antitumor vaccine. The study suggests PD-1 and PD-L1 may help tumors evade vaccines, supporting testing of therapeutic combinations in clinical trials.
The extent of resection in glioblastoma patients was found to be associated with improved overall and progression-free survival. Glioblastoma multiforme (GBM) patients who underwent gross total resection (GTR) showed a significant increase in one-year and two-year survival rates compared to those with subtotal resection or biopsy.
Researchers from UH Seidman Cancer Center will present data on a new online tool for estimating individualized survival probabilities in patients with newly diagnosed glioblastoma. The studies also explore promising new treatments, including pembrolizumab for head and neck squamous cell carcinoma, and improve patient participation in c...
Researchers have identified a group of immune system genes associated with glioblastoma multiforme survival. The eight-gene signature is linked to shorter survival times and more rapid disease progression, but may also identify potential targets for treatment.
Researchers identified a specific enzyme and signaling pathway involved in resistance to treatment, which can be targeted by other drugs for improved outcomes. Glioblastoma multiforme tumors were shown to manipulate their surrounding environment to evade therapy, leading to longer survival when treated with combination therapies.
A clinical study reveals that glioblastoma subtypes develop in distinct brain regions, shedding light on the origins of these aggressive brain cancers. The discovery may lead to more effective personalized treatment approaches by identifying specific subtype markers.
A gene known as OSMR plays a key role in driving the growth of glioblastoma tumors, according to a new study. Researchers discovered that by disabling OSMR, glioblastoma cells lose their ability to form tumors in mice, suggesting a potential target for treatments.
A team of researchers has identified an alternate mechanism for evading therapy in brain cancer cells, which adapts within as little as three days of treatment. By targeting both the original and new signaling pathways, they can durably suppress tumor growth.
Two studies from Massachusetts General Hospital suggest that targeting both VEGF and Ang-2 pathways can normalize tumor blood vessels and shift immune cells towards an anti-tumor state. This approach has shown promise in slowing glioblastoma growth and improving survival rates.
Researchers at Ohio State University Wexner Medical Center have identified altered metabolism of methionine and tryptophan as a driving force behind glioblastoma progression. Restricting dietary intake of these amino acids may slow tumor growth and improve treatment outcomes.
Glioblastoma patients with high BIRC3 expression have shorter overall survival rates, while those with low expression live longer. Analyzing BIRC3 tissue levels could help detect treatment resistance earlier.
Researchers at Nagoya University developed a novel immunotherapy using genetically engineered T cells that target podoplanin, a key protein associated with GBM progression. This treatment successfully arrested tumor growth in 60% of mice and demonstrated promise for treating patients with relapsed or resistant tumors.
Researchers identified SGEF as a target for new brain cancer therapies in a study published by Molecular Cancer Research. The protein promotes the survival of glioblastoma tumor cells and helps the cancer invade brain tissue.
Researchers at Salk Institute identify nuclear factor kB as a key player in glioblastoma multiforme proliferation. Targeting this protein with NBD peptide or Timp1 gene slows tumor growth and increases mouse survival time, offering potential new treatment avenues.
Researchers found that combining TTFields with chemotherapy significantly improved progression-free and overall survival for patients with glioblastoma. The study, published in JAMA, suggests a potential new treatment approach for this devastating brain tumor.
The EORTC trial 26101 found that bevacizumab treatment in progressive glioblastoma patients did not confer a survival advantage despite prolonged progression-free survival. The combination of bevacizumab and lomustine may prolong PFS but does not impact overall survival.
Researchers develop nanoparticles that can carry therapeutics across the brain blood barrier, offering new hope for treating glioblastoma multiforme. The 3HM nanocarriers show promising attributes for treating brain cancers.